• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Precision Coating, a Katahdin company, Acquired by Integer

    2/4/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ITGR alert in real time by email

    Katahdin Industries, LLC is pleased to announce the sale of substantially all of the assets of Precision Coating to Integer Holdings Corporation. The transaction closed on January 7, 2025. Precision Coating provides global Medtech customers with innovative products and services to enhance the surface functionality of patient-critical products.

    Since 2006, Precision Coating has built a highly specialized proprietary coatings platform in the medical technology supply chain. The portfolio build, positioning and growth trajectory was accelerated through five acquisitions including CHN Metal Finishing (2008), Medi-Solve (2008), Boyd Coatings Research (2015), a merger with N2 Biomedical (2021), and Providence Texture (2023). A nearly ten-fold increase in scale over the hold period was further facilitated by investments in data systems, automation, materials development, and greenfield expansion in Costa Rica. The company currently operates out of four North American sites and one in Costa Rica.

    "From the very beginning, we identified precise control over surface treatment as a key feature in the medical device manufacturing process," commented Tim Cabot, Chairman of Katahdin. "We also saw a gap in the market to address unique coating-as-a-service needs for medical device customers and to position the company to become a fully capable contract manufacturing services provider for the full life cycle of each product we work on. Over time our market focus has also allowed us to expand and enhance our specialized, high-value, and innovative application solutions, including GlideLine™, our proprietary fluoropolymer coatings for medical devices; MICRALOX®, our patented anodic coatings for re-usable medical instruments; and IonGuard®, our proprietary ion treatment for implants."

    Bill Ellerkamp, President of Precision Coating, added, "We are very excited about the acquisition of Precision Coating by Integer. We are proud of the strong and defensible position we've built in the proprietary coatings segment of the Medtech industry and the exceptional company culture we've created. Integer is uniquely positioned to capitalize on the strengths of our technologies and our respective cultures are well aligned. We are confident in the future of Precision Coating as part of Integer."

    Piper Sandler & Co. served as exclusive financial advisor to Katahdin and Ruberto, Israel, & Weiner, P.C. served as legal advisors.

    About Katahdin

    Katahdin Industries, LLC is a closely held investment corporation with both individual and institutional ownership. Following Katahdin's 2021 merger with N2 Biomedical, Ampersand Capital Partners became a minority shareholder and provided strategic guidance cultivated from a deep history of investing in medical contract design and manufacturing organizations. Tim Cabot and Bob DeAngelis led the original acquisition and company build out through 2018 when Bill Ellerkamp became President of Precision Coating. Additional information about Precision Coating is available at www.precisioncoating.com.

    About Ampersand Capital Partners

    Founded in 1988, Ampersand Capital Partners is a middle market private equity firm with $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit www.ampersandcapital.com or follow us on LinkedIn.

    About Integer®

    Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net 

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250204761444/en/

    Bill Ellerkamp, President of Precision Coating

    978.562.7561

    Get the next $ITGR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ITGR

    DatePrice TargetRatingAnalyst
    10/24/2025Buy → Hold
    Argus
    10/24/2025$80.00Overweight → Equal Weight
    Wells Fargo
    10/24/2025$77.00Buy → Neutral
    Citigroup
    10/24/2025$87.00Buy → Neutral
    BofA Securities
    10/24/2025Buy → Hold
    The Benchmark Company
    5/22/2025$140.00Neutral → Buy
    Citigroup
    3/28/2025$145.00Outperform
    Raymond James
    2/21/2025Outperform → Perform
    Oppenheimer
    More analyst ratings

    $ITGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Integer Holdings downgraded by Argus

    Argus downgraded Integer Holdings from Buy to Hold

    10/24/25 2:15:30 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Integer Holdings from Overweight to Equal Weight and set a new price target of $80.00

    10/24/25 8:57:52 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings downgraded by Citigroup with a new price target

    Citigroup downgraded Integer Holdings from Buy to Neutral and set a new price target of $77.00

    10/24/25 8:57:52 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Integer to Highlight Integrated R&D Solutions and Expanded Coating Capabilities During MD&M West 2026

    PLANO, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, will exhibit during MD&M West 2026 in Anaheim, Calif., Feb. 3 – 5. Integer will unveil a significantly expanded 20 x 50 sq. ft. new booth #3201, showcasing the company's full range of customer solutions. On prominent display will be R&D Velocity, Integer's integrated R&D ecosystem connecting design, prototyping and manufacturing to help medical device companies develop products that are manufacturable from the start, accelerating the time between design and manufacturability. "Whether you're

    1/28/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Announces Conference Call to Discuss Fourth Quarter and Full Year 2025 Results

    PLANO, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it will webcast its conference call discussing financial results and business highlights for the fourth quarter and year ended Dec. 31, 2025, on Thursday, Feb. 19, 2026, at 8 a.m. CT / 9 a.m. ET. Other forward-looking and material information may also be discussed during this call. The company will issue a news release announcing financial results for the fourth quarter and full year on Feb. 19 prior to the conference call. Conference call details: Date: Thursday, Feb. 19, 2026Time: 8 a.m. CT / 9 a.m. ETDomestic dial-in number: (800) 715-9871International dial-in number: (646) 30

    1/22/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer to Showcase Innovations in Neuromodulation, Miniaturized Active Implantable Device Technology During NANS 2026 Annual Meeting

    PLANO, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) --  Integer Holdings Corporation (NYSE:ITGR), one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, will join global medtech leaders and innovators in exhibiting at the North American Neuromodulation Society (NANS) Annual Meeting in Las Vegas from Jan. 22 – 25, 2026. At booth #115, Integer will spotlight its latest advancements in neuromodulation and next-generation miniaturized active implantable medical devices (AIMDs). These innovations are designed to accelerate development timelines and reduce risk for medical device companies bringing novel therapies to market. "Miniaturization is tra

    1/14/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Corporate Controller Thomas Tommy P converted options into 795 shares and covered exercise/tax liability with 334 shares, increasing direct ownership by 13% to 4,057 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    1/21/26 8:53:09 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP, Global Ops and Manufactur Harris John A covered exercise/tax liability with 552 shares and converted options into 1,148 shares, increasing direct ownership by 10% to 6,662 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    1/21/26 8:52:27 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP, Chief Financial Officer Smith Diron converted options into 3,360 shares and covered exercise/tax liability with 920 shares, increasing direct ownership by 32% to 10,138 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    1/21/26 8:51:49 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Global Ops and Manufactur Harris John A bought $115,500 worth of shares (1,650 units at $70.00), increasing direct ownership by 37% to 6,066 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/13/25 4:18:50 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP, Chief Financial Officer Smith Diron bought $74,967 worth of shares (1,116 units at $67.19), increasing direct ownership by 17% to 7,698 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/10/25 8:19:02 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Capps Cheryl C bought $106,720 worth of shares (1,600 units at $66.70), increasing direct ownership by 16% to 11,702 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/10/25 8:16:21 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    SEC Filings

    View All

    Integer Holdings Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Integer Holdings Corp (0001114483) (Filer)

    11/4/25 8:01:46 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Integer Holdings Corp (0001114483) (Filer)

    10/24/25 8:01:29 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form 10-Q/A filed by Integer Holdings Corporation

    10-Q/A - Integer Holdings Corp (0001114483) (Filer)

    10/24/25 7:36:36 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Leadership Updates

    Live Leadership Updates

    View All

    Payman Khales Assumes Role as Integer President and CEO

    ~ Planned Leadership Transition Completed ~ PLANO, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today shared that, as part of a planned transition originally announced in April 2025, Payman Khales has assumed the role of President and Chief Executive Officer. He also joins the company's Board of Directors. He succeeds Joseph Dziedzic, who is retiring after eight years of distinguished service as Integer President and CEO and will continue to serve as an advisor through March 31, 2026, to support a smooth transition. Mr. Khales joined Integer in 2018 as Preside

    10/24/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Appoints Michael Coyle to Board of Directors

    ~ New Director Brings Extensive Medical Device Industry Leadership and Technology Experience to Integer Board ~ PLANO, Texas, July 10, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced it has appointed Michael Coyle to its Board of Directors. Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee. He most recently served as president and CEO of iRhythm Technologies, a digital healthcare company. Bef

    7/10/25 4:52:01 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

    SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

    12/7/22 4:05:00 PM ET
    $EAR
    $ITGR
    $VAPO
    Medical Specialities
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    $ITGR
    Financials

    Live finance-specific insights

    View All

    Integer Announces Conference Call to Discuss Fourth Quarter and Full Year 2025 Results

    PLANO, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it will webcast its conference call discussing financial results and business highlights for the fourth quarter and year ended Dec. 31, 2025, on Thursday, Feb. 19, 2026, at 8 a.m. CT / 9 a.m. ET. Other forward-looking and material information may also be discussed during this call. The company will issue a news release announcing financial results for the fourth quarter and full year on Feb. 19 prior to the conference call. Conference call details: Date: Thursday, Feb. 19, 2026Time: 8 a.m. CT / 9 a.m. ETDomestic dial-in number: (800) 715-9871International dial-in number: (646) 30

    1/22/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings Corporation Reports Third Quarter 2025 Results

    ~ Continued strong sales and profit growth in 3Q25 ~~ Updating 2025 sales and profit outlook; providing preliminary outlooks for 2026 and 2027 ~ PLANO, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended September 26, 2025. Third Quarter 2025 Highlights (compared to Third Quarter 2024, except as noted) Sales increased 8% to $468 million, with organic growth of 7%.GAAP operating income decreased $2 million to $56 million, a decrease of 3%. Non-GAAP adjusted operating income increased $10 million to $86 million, an increase of 14%.GAAP income from continuing operations increased $3 million to $40 million, an

    10/23/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Announces Conference Call to Discuss Third Quarter 2025 Results

    PLANO, Texas, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR) announced today that it will webcast its conference call discussing financial results and business highlights for the third quarter ended Sept. 26, 2025, on Thursday, Oct. 23, 2025, at 8 a.m. CT / 9 a.m. ET. Other forward-looking and material information may also be discussed during this call. The company will issue a news release announcing financial results for the third quarter on Oct. 23 prior to the conference call. Conference call details: Date: Thursday, Oct. 23, 2025Time: 8 a.m. CT / 9 a.m. ETDomestic dial-in number: (800) 715-9871International dial-in number: (646) 307-1963Conference ID: 3

    9/25/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

    SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

    2/9/24 9:59:01 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

    SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

    1/30/24 1:15:44 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

    SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

    2/10/23 2:42:23 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care